Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Status:
Completed
Trial end date:
2017-08-15
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to look at participants with solid tumor malignancies
and specific mutations respond to treatment with everolimus.